

Thomas Eigentler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7190322/publications.pdf>

Version: 2024-02-01

258
papers

14,526
citations

31949

53
h-index

24961

109
g-index

293
all docs

293
docs citations

293
times ranked

15903
citing authors

#	ARTICLE	IF	CITATIONS
1	TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 833-840.	1.2	6
2	Benefits of a nationwide population-based skin cancer screening programme – still a controversial debate. <i>British Journal of Dermatology</i> , 2022, 186, 8-9.	1.4	2
3	Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma. <i>Annals of Oncology</i> , 2022, 33, 544-555.	0.6	12
4	Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. <i>Cancers</i> , 2022, 14, 1804.	1.7	4
5	Local Tumor Infiltration and Locoregional Recurrence in Desmoplastic Cutaneous Squamous Cell Carcinoma. <i>Dermatologic Surgery</i> , 2022, 48, 283-289.	0.4	1
6	Development of an Image Analysis-Based Prognosis Score Using Google’s Teachable Machine in Melanoma. <i>Cancers</i> , 2022, 14, 2243.	1.7	7
7	Genome-Wide Association Study Suggests the Variant rs7551288*A within the DHCR24 Gene Is Associated with Poor Overall Survival in Melanoma Patients. <i>Cancers</i> , 2022, 14, 2410.	1.7	2
8	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	0.8	33
9	Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy. <i>Cancers</i> , 2022, 14, 2992.	1.7	12
10	Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in <i>BRAF</i> ^{V600} mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9547-9547.	0.8	5
11	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced <i>BRAF</i> ^{V600} -positive melanoma: Interim analysis of the ImmunoCobiVem study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9548-9548.	0.8	6
12	Abstract LB058: Imaging of CD8+ cytotoxic T-cells by Zr-89-Df-IAB22M2C PET/MRI: First clinical experience in patients with metastatic cancer. <i>Cancer Research</i> , 2022, 82, LB058-LB058.	0.4	0
13	eHealth Literacy in German Skin Cancer Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8365.	1.2	5
14	What causes the death of patients with cutaneous squamous cell carcinoma? A prospective analysis in 1400 patients. <i>European Journal of Cancer</i> , 2022, 172, 182-190.	1.3	4
15	Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1263-1275.	2.0	8
16	Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1089-1099.	2.0	3
17	Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. <i>Targeted Oncology</i> , 2021, 16, 197-205.	1.7	12
18	Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 643156.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. European Journal of Cancer, 2021, 147, 170-181.	1.3	40
20	TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.. Journal of Clinical Oncology, 2021, 39, 9524-9524.	0.8	0
21	Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.. Journal of Clinical Oncology, 2021, 39, 9516-9516.	0.8	17
22	Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy â€“ A multicentre study of 90 patients from the German Dermat oncology Group. European Journal of Cancer, 2021, 149, 1-10.	1.3	10
23	Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. , 2021, 9, e002350.		11
24	Psychological Distress of Metastatic Melanoma Patients during Treatment with Immune Checkpoint Inhibitors: Results of a Prospective Study. Cancers, 2021, 13, 2642.	1.7	4
25	Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.. Journal of Clinical Oncology, 2021, 39, 9545-9545.	0.8	11
26	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. European Journal of Cancer, 2021, 148, 61-75.	1.3	15
27	Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma. Acta Radiologica, 2021, , 028418512110198.	0.5	5
28	Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. Pediatric Blood and Cancer, 2021, 68, e28992.	0.8	9
29	Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy. Academic Radiology, 2021, , .	1.3	2
30	Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). Cancer Research, 2021, 81, CT004-CT004.	0.4	28
31	1044P Sequential targeted and immunotherapies in stage IV melanoma. Annals of Oncology, 2021, 32, S875.	0.6	0
32	1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results. Annals of Oncology, 2021, 32, S886-S887.	0.6	1
33	1010P Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008. Annals of Oncology, 2021, 32, S853.	0.6	3
34	1079P Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naïve and pretreated patients with advanced melanoma within the German noninterventional study NICO. Annals of Oncology, 2021, 32, S894-S895.	0.6	0
35	1055P Prognostic relevance of tumor-infiltrating lymphocytes in early-stage melanoma. Annals of Oncology, 2021, 32, S880-S881.	0.6	0
36	Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition â€” A Descriptive Observational Retrospective Multicenter Analysis. Frontiers in Oncology, 2021, 11, 765608.	1.3	10

#	ARTICLE	IF	CITATIONS
37	Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany. <i>Acta Dermato-Venereologica</i> , 2021, 102, adv00637.	0.6	3
38	A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. , 2021, 9, e003261.		20
39	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10
40	Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. <i>Cancers</i> , 2021, 13, 6141.	1.7	11
41	Simultaneous targeted therapy for metastatic melanoma and hepatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 42-43.	0.4	1
42	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive <i>in vivo</i> ¹⁸ F-FDG-PET. <i>Theranostics</i> , 2020, 10, 925-937.	4.6	46
43	Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. <i>European Journal of Cancer</i> , 2020, 125, 38-45.	1.3	36
44	Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 136-139.	0.4	4
45	Late recurrence of melanoma after 10 years – Is the course of the disease different from early recurrences?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 977-983.	1.3	4
46	CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases. <i>European Journal of Radiology</i> , 2020, 131, 109242.	1.2	1
47	Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors. <i>American Journal of Pathology</i> , 2020, 190, 2155-2164.	1.9	8
48	Dermatofluoroscopy diagnostics in different pigmented skin lesions: Strengths and weaknesses. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 682-690.	0.4	3
49	Melanoma brain metastases – Interdisciplinary management recommendations 2020. <i>Cancer Treatment Reviews</i> , 2020, 89, 102083.	3.4	52
50	1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO. <i>Annals of Oncology</i> , 2020, 31, S746-S747.	0.6	1
51	Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade. <i>Annals of Internal Medicine</i> , 2020, 172, 836-837.	2.0	44
52	The evolving field of Dermatological oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV – UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	1.3	22
53	1102P Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study. <i>Annals of Oncology</i> , 2020, 31, S745.	0.6	4
54	1122P Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases. <i>Annals of Oncology</i> , 2020, 31, S755.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 395, 1558-1568.	6.3	188
56	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020, 38, 2543-2551.	0.8	40
57	Quality assurance in melanoma care: guideline-based quality indicators for melanoma – implementation, evaluation and update process. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 848-857.	0.4	7
58	Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. , 2020, 8, e000775.		113
59	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1835-1844.	6.3	423
60	Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. <i>Nature Communications</i> , 2020, 11, 1335.	5.8	75
61	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma – short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 275-294.	0.4	57
62	Prognostic Impact of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Results of a Prospective Study of 1,399 Tumors. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1968-1975.	0.3	29
63	Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2021-2025.	1.3	16
64	S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) – short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 400-413.	0.4	39
65	Primary Resistance to PD-1-Based Immunotherapy – A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , 2020, 12, 1027.	1.7	17
66	Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. , 2020, 8, e000333.		55
67	An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery – the BUMPER study. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa140.	0.4	6
68	Absolute and relative differential blood count predicts survival of AJCC stage I–III melanoma patients scheduled for sentinel lymph node biopsy. <i>Australasian Journal of Dermatology</i> , 2020, 61, e310-e318.	0.4	8
69	Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial. , 2020, , .		7
70	Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10070-10070.	0.8	5
71	Diagnostic Accuracy of Electrical Impedance Spectroscopy in Non-melanoma Skin Cancer. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00328.	0.6	8
72	Vorhersage des Therapieansprechens und des Überlebens von Melanompatienten unter Immuntherapie anhand prätherapeutischer klinischer und radiologischer Prädiktoren. , 2020, 192, .		0

#	ARTICLE	IF	CITATIONS
73	Patient-reported outcomes (PROs) from the phase III IMspire150 trial of atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in patients (pts) with <i>BRAF</i>^{V600+} melanoma.. Journal of Clinical Oncology, 2020, 38, 10073-10073.	0.8	2
74	A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors.. Journal of Clinical Oncology, 2020, 38, 3096-3096.	0.8	8
75	Chemosaturatıon mit perkutaner Leberperfusion von Melphalan bei Leber-dominant metastasiertem Aderhautmelanom. , 2020, 192, .		0
76	301â€...Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study. , 2020, , .		0
77	800â€...A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors. , 2020, , .		1
78	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PLoS ONE, 2019, 14, e0221301.	1.1	16
79	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma â€ results of a prospective biomarker study. , 2019, 7, 180.		137
80	5. Netzwerktreffen der zertifizierten Hautkrebszentren. JDDG - Journal of the German Society of Dermatology, 2019, 17, 763-764.	0.4	0
81	A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours. Annals of Oncology, 2019, 30, v191-v192.	0.6	0
82	Efficacy and safety of dabrafenib and trametinib in patients with metastatic BRAFV600 mutation-positive melanoma in the real-world setting: Interim results of the non-interventional COMBI-r study. Annals of Oncology, 2019, 30, v544-v545.	0.6	2
83	Phase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy. Annals of Oncology, 2019, 30, v559.	0.6	4
84	Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED). Annals of Oncology, 2019, 30, v903-v904.	0.6	6
85	Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal antiâ€PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC). Annals of Oncology, 2019, 30, v536-v537.	0.6	5
86	Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI). Annals of Oncology, 2019, 30, v549-v550.	0.6	0
87	Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy. European Journal of Radiology, 2019, 121, 108688.	1.2	20
88	Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. , 2019, 7, 299.		108
89	Local surgical treatment of cutaneous squamous cell carcinoma: deficits and controversies in the literature. JDDG - Journal of the German Society of Dermatology, 2019, 17, 999-1004.	0.4	7
90	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1547-1559.	2.0	32

#	ARTICLE	IF	CITATIONS
91	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. <i>Journal of Clinical Oncology</i> , 2019, 37, 3142-3151.	0.8	83
92	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , 2019, 116, 207-215.	1.3	35
93	Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. <i>ESMO Open</i> , 2019, 4, e000491.	2.0	140
94	S2 Leitlinie Merkelzellkarzinom (MZK, MCC, neuroendokrines Karzinom der Haut) – Update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 562-577.	0.4	13
95	Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. <i>Cancer Imaging</i> , 2019, 19, 31.	1.2	39
96	S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 562-576.	0.4	27
97	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1299-1307.e7.	0.6	8
98	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	0.8	258
99	Medical treatment of advanced cutaneous squamous cell carcinoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 38-43.	1.3	52
100	Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis. <i>Immunotherapy</i> , 2019, 11, 297-309.	1.0	22
101	Time trends in incidence and mortality of cutaneous melanoma in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1272-1280.	1.3	49
102	Abstract LB-021: Intratumoral RNA-based TLR-7/8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors. , 2019, , .		3
103	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. <i>Deutsches &#x0308;rzteblatt International</i> , 2019, 116, 497-504.	0.6	15
104	Abstract LB-021: Intratumoral RNA-based TLR-7/8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors. , 2019, , .		0
105	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 825-834.	2.0	91
106	Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: results of a prospective multicentre clinical study in 476 pigmented lesions. <i>British Journal of Dermatology</i> , 2018, 179, 478-485.	1.4	17
107	Immune checkpoint blockade therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1403-1414.	1.5	79
108	Safety of shortened infusion times for combined ipilimumab and nivolumab. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 135-140.	2.0	3

#	ARTICLE	IF	CITATIONS
109	Intraoperative 3D perfusion measurement during chemoembolisation with doxorubicin-eluting beads in liver metastases of malignant melanoma. <i>European Radiology</i> , 2018, 28, 1456-1464.	2.3	5
110	Lymph node dissection for melanoma using tumescence local anaesthesia: an observational study. <i>European Journal of Dermatology</i> , 2018, 28, 177-185.	0.3	17
111	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. <i>European Journal of Cancer</i> , 2018, 98, 10-16.	1.3	57
112	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. <i>British Journal of Cancer</i> , 2018, 119, 339-346.	2.9	83
113	Patient acceptance and trust in automated computer-assisted diagnosis of melanoma with dermatofluoroscopy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 854-859.	0.4	18
114	Patientenakzeptanz und Vertrauen in die automatisierte, computergestützte Diagnostik des Melanoms mithilfe der Dermatofluoroskopie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 854-860.	0.4	7
115	Vemurafenib. <i>Recent Results in Cancer Research</i> , 2018, 211, 77-89.	1.8	52
116	Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study. <i>Journal of Clinical Oncology</i> , 2018, 36, 9527-9527.	0.8	25
117	Melanom der Vulva. , 2018, , 155-173.		0
118	Melanom der Vagina. , 2018, , 273-281.		0
119	Self-detection frequency and recognition patterns in medium to high-risk cutaneous melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 61-67.	0.4	2
120	GSTP1 does not modify MC1R effects on melanoma risk. <i>Experimental Dermatology</i> , 2017, 26, 730-733.	1.4	12
121	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017, 57, 36-49.	3.4	257
122	S3 Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms Update 2015/2016, Kurzversion 2.0. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, e1-e41.	0.4	29
123	Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. <i>European Journal of Cancer</i> , 2017, 82, 56-65.	1.3	162
124	Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1312-1318.	3.3	23
125	Prognostic impact of tumour burden measured by quantitative real-time PCR from sentinel lymph nodes of melanoma patients: data from 10-year follow-up. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 703-708.	1.2	4
126	Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma: safety and efficacy in a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 441-449.	2.0	23

#	ARTICLE	IF	CITATIONS
127	The tanning habits and interest in sunscreen of Google users: what happened in 12 years?. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2017, 33, 68-74.	0.7	12
128	Incidence, Mortality, and Trends of Nonmelanoma Skin Cancer in Germany. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1860-1867.	0.3	149
129	The need for psycho-oncological support for melanoma patients. <i>Medicine (United States)</i> , 2017, 96, e7987.	0.4	12
130	Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). <i>Klinische Padiatrie</i> , 2017, 229, 322-328.	0.2	16
131	Pembrolizumab-induced hepatitis: diagnosis and treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 933-935.	0.4	4
132	Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2570-2577.	0.3	24
133	Type 1 diabetes mellitus caused by treatment with low-dose interferon- β in a melanoma patient. <i>Melanoma Research</i> , 2017, 27, 516-518.	0.6	7
134	Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2309-2315.	0.3	124
135	Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. <i>Melanoma Research</i> , 2017, 27, 321-325.	0.6	46
136	Häufigkeit und Muster der Tumorerkennung nach Selbstuntersuchung bei Mittel- bis Hochrisiko-Melanompatienten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 61-69.	0.4	0
137	Imaging characteristics of cardiac metastases in patients with malignant melanoma. <i>Cancer Imaging</i> , 2017, 17, 19.	1.2	12
138	Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen. <i>European Radiology</i> , 2017, 27, 2538-2545.	2.3	10
139	Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 533-540.	1.2	41
140	Interest in tanning beds and sunscreen in German-speaking countries. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1192-1198.	0.4	6
141	Das Interesse an Solarien und Sonnenschutz im deutschsprachigen Raum. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1192-1198.	0.4	0
142	Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. <i>Oncotarget</i> , 2017, 8, 79731-79741.	0.8	77
143	Zweites Netzwerktreffen der zertifizierten Hauttumorzentren. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 1051-1052.	0.4	0
144	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 210-225.	1.3	490

#	ARTICLE	IF	CITATIONS
145	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 190-209.	1.3	546
146	Mitotic rate in primary melanoma: interobserver and intraobserver reliability, analyzed using H&E sections and immunohistochemistry. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 910-915.	0.4	12
147	Mitoserate beim primären Melanom: Interobserver- und Intraobserver-Reproduzierbarkeit am HE-Schnitt und in der Immunhistologie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 910-916.	0.4	12
148	Adjuvant treatment with pegylated interferon α -2a versus low-dose interferon α -2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. <i>Annals of Oncology</i> , 2016, 27, 1625-1632.	0.6	23
149	PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2016, 22, 5818-5828.	3.2	68
150	Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 951-959.	2.0	62
151	CT imaging of bone and bone marrow infiltration in malignant melanoma – Challenges and limitations for clinical staging in comparison to 18FDG-PET/CT. <i>European Journal of Radiology</i> , 2016, 85, 732-738.	1.2	43
152	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	3.2	459
153	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	3.4	354
154	Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 482-488.	3.3	37
155	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. <i>Oncotarget</i> , 2016, 7, 36130-36137.	0.8	12
156	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 351.	1.8	56
157	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1075-1082.	2.0	16
158	Targeted Therapies for Melanoma. , 2015, , 1529-1541.		0
159	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	5.1	1,419
160	443 paediatric cases of malignant melanoma registered with the German Central Malignant Melanoma Registry between 1983 and 2011. <i>European Journal of Cancer</i> , 2015, 51, 861-868.	1.3	45
161	Prospective evaluation of follow-up in melanoma patients in Germany – Results of a multicentre and longitudinal study. <i>European Journal of Cancer</i> , 2015, 51, 653-667.	1.3	46
162	Sentinel Lymph Node Dissection in Head and Neck Melanoma has Prognostic Impact on Disease-Free and Overall Survival. <i>Annals of Surgical Oncology</i> , 2015, 22, 4073-4080.	0.7	28

#	ARTICLE	IF	CITATIONS
163	Screening for skin cancer in bank and insurance employees: risk profile and correlation of self and physician's assessment. <i>International Journal of Dermatology</i> , 2015, 54, 419-423.	0.5	0
164	Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study. <i>British Journal of Dermatology</i> , 2015, 172, 1646-1650.	1.4	4
165	Lack of activity of betulin-based Oleogel-S10 in the treatment of actinic keratoses: a randomized, multicentre, placebo-controlled double-blind phase II trial. <i>British Journal of Dermatology</i> , 2015, 172, 926-932.	1.4	11
166	Survival According to BRAF-V600 Tumor Mutations " An Analysis of 437 Patients with Primary Melanoma. <i>PLoS ONE</i> , 2014, 9, e86194.	1.1	42
167	BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy. <i>PLoS ONE</i> , 2014, 9, e89218.	1.1	18
168	Vemurafenib. <i>Recent Results in Cancer Research</i> , 2014, 201, 215-225.	1.8	30
169	Epidemiology of Skin Cancer. , 2014, 810, 120-140.		406
170	Limited efficacy of intratumoral IL-2 applied to large melanoma metastases. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1231-1232.	2.0	5
171	Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19"IL2 Results in Sustained Clinical and Systemic Immunologic Responses. <i>Cancer Immunology Research</i> , 2014, 2, 668-678.	1.6	81
172	Effectiveness and Tolerability of Ipilimumab. <i>Journal of Immunotherapy</i> , 2014, 37, 374-381.	1.2	23
173	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 4390-4399.	3.2	36
174	In melanoma, Hippo signaling is affected by copy number alterations and YAP1 overexpression impairs patient survival. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 671-673.	1.5	28
175	Follow-up in patients with low-risk cutaneous melanoma: is it worth it?. <i>Melanoma Management</i> , 2014, 1, 115-125.	0.1	2
176	Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9031-9031.	0.8	2
177	Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9041-9041.	0.8	2
178	Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)"Decog-trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9071-9071.	0.8	1
179	Proliferative Activity, Chromosomal Aberrations, and Tumor-Specific Mutations in the Differential Diagnosis between Blue Nevi and Melanoma. <i>American Journal of Pathology</i> , 2013, 182, 640-645.	1.9	33
180	Protein kinase inhibitors in melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2195-2201.	0.9	9

#	ARTICLE	IF	CITATIONS
181	Effective Combination of Photodynamic Therapy and Imiquimod 5% Cream in the Treatment of Actinic Keratoses: Three Cases. <i>BioMed Research International</i> , 2013, 2013, 1-5.	0.9	10
182	S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. <i>Melanoma Research</i> , 2013, 23, 396-401.	0.6	22
183	Targeting hyperactivation of the <sc>AKT</sc> survival pathway to overcome therapy resistance of melanoma brain metastases. <i>Cancer Medicine</i> , 2013, 2, 76-85.	1.3	126
184	Malignes Melanom S3-Leitlinie â€œDiagnostik, Therapie und Nachsorge des Melanomsâ€•. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1-126.	0.4	9
185	Malignant Melanoma S3-Guideline â€œDiagnosis, Therapy and Follow-up of Melanomaâ€•. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1-116.	0.4	122
186	S3â€œGuideline â€œDiagnosis, therapy and followâ€•up of melanomaâ€•â€œ short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 563-602.	0.4	63
187	Brief S2k guidelines â€œ Cutaneous squamous cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 37-45.	0.4	50
188	Molekulargenetische Klassifikation schwieriger melanozytÃ¶rer Tumoren. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 12-19.	0.4	1
189	Molecular genetic classification of difficult melanocytic tumors. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 11-18.	0.4	7
190	Prognostic Factors of Melanoma Patients with Satellite or In-Transit Metastasis at the Time of Stage III Diagnosis. <i>PLoS ONE</i> , 2013, 8, e63137.	1.1	26
191	Melanoma Patients with Unknown Primary Site or Nodal Recurrence after Initial Diagnosis Have a Favourable Survival Compared to Those with Synchronous Lymph Node Metastasis and Primary Tumour. <i>PLoS ONE</i> , 2013, 8, e66953.	1.1	22
192	Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy. <i>PLoS ONE</i> , 2013, 8, e81624.	1.1	54
193	The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20050-e20050.	0.8	2
194	The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. <i>PLoS ONE</i> , 2013, 8, e53745.	1.1	414
195	Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. <i>British Journal of Cancer</i> , 2012, 107, 422-428.	2.9	129
196	CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 299-303.	0.3	23
197	Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1835-1841.	0.8	112
198	Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 37-45.	0.6	84

#	ARTICLE	IF	CITATIONS
199	Recurrent nodules in a periauricular plaque-type blue nevus with fatal outcome. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 1088-1093.	0.7	29
200	Prognosis of Sentinel Node Staged Patients with Primary Cutaneous Melanoma. <i>PLoS ONE</i> , 2012, 7, e29791.	1.1	14
201	Open label randomized study comparing 3-months vs. 6-months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 48-53.	1.3	52
202	Comparison and evaluation of the current staging of cutaneous carcinomas. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 579-586.	0.4	47
203	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8526-8526.	0.8	0
204	Ipilimumab use in a named-patient program in metastatic melanoma: Experiences in 185 German patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19031-e19031.	0.8	0
205	Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects. <i>Oncologist</i> , 2011, 16, 5-24.	1.9	472
206	A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. <i>European Journal of Cancer</i> , 2011, 47, 1977-1989.	1.3	56
207	Health-related Quality of Life Before and During Adjuvant Interferon- α Treatment for Patients With Malignant Melanoma (DeCOG-Trial). <i>Journal of Immunotherapy</i> , 2011, 34, 403-408.	1.2	32
208	Sex differences in survival of cutaneous melanoma are age dependent. <i>Melanoma Research</i> , 2011, 21, 244-252.	0.6	36
209	Melanoma of unknown primary is correctly classified by the AJCC melanoma classification from 2009. <i>Melanoma Research</i> , 2011, 21, 228-234.	0.6	29
210	Oncogenetics of melanoma: basis for molecular diagnostics and therapy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 510-516.	0.4	3
211	Histopathological diagnostics of malignant melanoma in accordance with the recent AJCC classification 2009: Review of the literature and recommendations for general practice. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 690-699.	0.4	26
212	Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 487-493.	2.0	51
213	Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. <i>Cancer</i> , 2011, 117, 1697-1703.	2.0	118
214	A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 7732-7742.	3.2	134
215	Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma. <i>PLoS ONE</i> , 2011, 6, e16882.	1.1	22
216	Depressive Mood Changes and Psychiatric Symptoms During 12-month Low-dose Interferon- α Treatment in Patients With Malignant Melanoma. <i>Journal of Immunotherapy</i> , 2010, 33, 106-114.	1.2	36

#	ARTICLE	IF	CITATIONS
217	Sentinel Lymph Node Dissection in Primary Melanoma Reduces Subsequent Regional Lymph Node Metastasis as Well as Distant Metastasis After Nodal Involvement. <i>Annals of Surgical Oncology</i> , 2010, 17, 129-137.	0.7	45
218	High response rate after intratumoral treatment with interleukin-2. <i>Cancer</i> , 2010, 116, 4139-4146.	2.0	120
219	Determinants of survival in patients with brain metastases from cutaneous melanoma. <i>British Journal of Cancer</i> , 2010, 102, 1213-1218.	2.9	147
220	Efficacy of Low-Dose Interferon α 2a 18 Versus 60 Months of Treatment in Patients With Primary Melanoma of \leq 1.5 mm Tumor Thickness: Results of a Randomized Phase III DeCOG Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 841-846.	0.8	76
221	Melanoma staging: Facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 275-280.	0.8	21
222	Incisional biopsy and melanoma prognosis: Facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 316-318.	0.8	83
223	Excision guidelines and follow-up strategies in cutaneous melanoma: Facts and controversies. <i>Clinics in Dermatology</i> , 2010, 28, 311-315.	0.8	23
224	Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?. <i>Melanoma Research</i> , 2010, 20, 240-246.	0.6	46
225	Prospective Randomized Multicenter Adjuvant Dermatologic Cooperative Oncology Group Trial of Low-Dose Interferon Alfa-2b With or Without a Modified High-Dose Interferon Alfa-2b Induction Phase in Patients With Lymph Node-Negative Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3496-3502.	0.8	33
226	Clinical course and prognostic factors of Merkel cell carcinoma of the skin. <i>British Journal of Dermatology</i> , 2009, 161, 90-94.	1.4	36
227	Inflammatory nodules around the axilla: an uncommon localization of orf virus infection. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 240-242.	0.6	14
228	Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 863-868.	0.6	18
229	Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients. <i>Journal of Immunotherapy</i> , 2009, 32, 498-507.	1.2	301
230	Costs of the detection of metastases and follow-up examinations in cutaneous melanoma. <i>Melanoma Research</i> , 2009, 19, 50-57.	0.6	50
231	Cutaneous Metastases of Melanoma: New Treatment Options. , 2009, , 591-598.		0
232	Age and gender are significant independent predictors of survival in primary cutaneous melanoma. <i>Cancer</i> , 2008, 112, 1795-1804.	2.0	211
233	Adjuvant low-dose interferon α 2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. <i>Annals of Oncology</i> , 2008, 19, 1195-1201.	0.6	122
234	Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA. <i>Journal of Immunotherapy</i> , 2008, 31, 180-188.	1.2	216

#	ARTICLE	IF	CITATIONS
235	Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. <i>Melanoma Research</i> , 2008, 18, 353-358.	0.6	24
236	Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. <i>Melanoma Research</i> , 2008, 18, 274-278.	0.6	80
237	Efficacy of interferon alpha 2a in 18 versus 60 months of treatment in patients with primary melanoma of ≤ 1.5 mm tumor thickness: A randomized phase III DeCOG trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 9032-9032.	0.8	5
238	Diagnosis and treatment of cutaneous melanoma: state of the art 2006*. <i>Melanoma Research</i> , 2007, 17, 117-127.	0.6	192
239	Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. <i>European Journal of Cancer</i> , 2007, 43, 557-564.	1.3	188
240	A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 616-621.	0.6	84
241	Improvement of overall survival of patients with cutaneous melanoma in Germany, 1976-2001. <i>Cancer</i> , 2007, 109, 1174-1182.	2.0	47
242	Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. <i>European Journal of Cancer</i> , 2006, 42, 342-350.	1.3	100
243	Metastatic glucagonoma: Treatment with liver transplantation. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 344-347.	0.6	17
244	Plasma Cell-Rich Rejection Processes in Renal Transplantation: Morphology and Prognostic Relevance. <i>Transplantation</i> , 2006, 81, 986-991.	0.5	54
245	The incidence and mortality of cutaneous melanoma in southern Germany. <i>Cancer</i> , 2006, 107, 1331-1339.	2.0	119
246	A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 8044-8044.	0.8	17
247	Development of prognostic factors and survival in cutaneous melanoma over 25 years. <i>Cancer</i> , 2005, 103, 616-624.	2.0	93
248	Malignant Melanoma: Classification and Staging of Malignant Melanoma. , 2005, 39, 149-158.		3
249	Imiquimod in the treatment of extensive recurrent lentigo maligna. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, S51-S52.	0.6	36
250	Acquired perforating collagenosis in Hodgkin's disease. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 922.	0.6	18
251	Prognostic Factors of Thin Cutaneous Melanoma: An Analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. <i>Journal of Clinical Oncology</i> , 2004, 22, 3660-3667.	0.8	112
252	Impact of Ulceration in Stages I to III Cutaneous Melanoma As Staged by the American Joint Committee on Cancer Staging System: An Analysis of the German Central Malignant Melanoma Registry. <i>Journal of Clinical Oncology</i> , 2004, 22, 4376-4383.	0.8	52

#	ARTICLE	IF	CITATIONS
253	Alopecia areata Induced by Adjuvant Treatment with Alpha-Interferon in Malignant Melanoma?. Dermatology, 2004, 209, 249-250.	0.9	14
254	Malignant blue naevus of the scalp. Lancet Oncology, The, 2004, 5, 429.	5.1	0
255	Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. British Journal of Cancer, 2003, 89, 1620-1626.	2.9	167
256	Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncology, The, 2003, 4, 748-759.	5.1	292
257	Fortgeschrittenes malignes Melanom: Kernpunkte der aktualisierten Leitlinie. , 0, , .		0
258	Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Frontiers in Immunology, 0, 13, .	2.2	2